Market Size (2016)
2016
$2.25B
Vertical: HealthcareBase Year: 201811 Sections
Market Size (2016)
2016
$2.25B
Projected (2025)
2025
$6.90B
CAGR (2016–2025)
13.3%
13.3%Key Players
109+
1.1 OVERVIEw
Dermal fillers are minimally invasive procedures used as anti-aging solutions to reduce facial lines and restore firmness. These are soft tissue fillers injected into the skin to resolve skin-related problems such as scars, wrinkles, and smoothens the skin using various dermal fillers such as hyaluronic acid, polymers and particles, and collagen.
Key factors that drive the dermal fillers market are the rising preference for non-invasive aesthetic procedures, an increasing number of plastic surgeons performing aesthetic procedures, and cost-effective alternatives to cosmetic surgeries. Also, the increase in per capita disposable income boosts the growth of the global dermal fillers market. However, factors such as side-effects associated with dermal fillers and the black market of dermal fillers and effects of unregistered practitioners hamper the market growth. The increasing number of clinical trial studies and rising demand for minimally invasive procedures act as an opportunity for the market.
The aesthetics Market market is projected to grow at a CAGR of 13.3% from 2016 to 2025.
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Size (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe scope of the global dermal fillers market study includes market size analysis and a detailed analysis of the manufacturer’s products and strategies. The market has been segmented based on type, brand, application, and region.
1.1 Research Objective
¡ To provide a comprehensive analysis of the global dermal fillers market and its sub-segments, thereby providing a detailed structure of the industry
¡ To provide detailed insights into factors driving and restraining the growth of the global dermal fillers market
¡ To estimate the market size of the global dermal fillers market where 2016 to 2017 would be the historic period, 2018 shall be the base year, and 2019 to 2025 will be the forecast period for the study
¡ To provide country-wise market value analysis for various segments of the global dermal fillers market
¡ To provide strategic profiling of key companies (manufacturers and distributors) present across the globe and comprehensively analyze their competitiveness/competitive landscape in this market
¡ To provide a distribution chain analysis/value chain for the global dermal fillers market
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2018
Historical Period
2016 – 2018
Forecast Period
2018 – 2025
Primary Interviews
150+
Historical data (2016–2018) and forecast period (2018–2025)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans1.1.1 THREAT OF NEW ENTRANTS
The threat of new entrants is moderate to high in the global dermal fillers market. Any manufacturing company trying to enter the market is required to accept or abide by the mandatory regulatory standards. The dermal fillers market is also characterized by a reasonable degree of brand loyalty, where establishing a brand name is difficult for newcomers. However, the cost involved in R&D is comparatively high, which does not comfort the new entrants to enter the market easily. Recently, due to different cases related to horrific adverse events of dermal fillers, regulatory authorities have made approvals stricter and started scrutinized checks for every product with more detail. Thus, the threat of new entrants remains moderate to high.
1.1.2 Bargaining Power of Suppliers
The suppliers in the global dermal fillers market are the developers and manufacturers of facial injectable products or dermal fillers. There is a large number of suppliers in the global dermal fillers market, thus leading to a high amount of bargaining power in the market. The switching cost of these suppliers is also high as suppliers tend to enter into long term associations with cosmetic professionals. However, developing countries in the Asia-Pacific region consist of a large number of suppliers that offer these injectable facial products at a reasonable rate. This leads to the high bargaining power of suppliers, and the profit potential of the global dermal fillers market is increased.
1.1.3 Threat of Substitutes
The threat of substitutes in the global dermal fillers market is moderate to high. Buyer propensity to substitute is also a factor that should be given importance. The emerging trend of usage of botulinum toxin can hamper the growth of the market. There have been various cases where botulinum toxin has proved to be a better option. As per the Plastic Surgery Statistics Report published in 2018 by the American Society of Plastic Surgeons, the number of cosmetic minimally-invasive procedures involving the use of botulinum toxin type A was 7.43 million in 2018, whereas the processes involving the use of soft tissue fillers were 2.67 million in 2018 in the US. Thus, the threat of substitutes tends to be moderate to high.
1.1.4 Bargaining Power of Buyers
The bargaining power of buyers is moderate in the global dermal fillers market. The market has a large number of buyers comprising of various end users. The buyers of dermal fillers are moderately inclined towards dermal fillers manufacturers. Moreover, buyers can exert moderate pressure on the manufacturers to provide high-quality products and services. Hence, with the high level of products and services provided by the dermal fillers’ manufacturers, the bargaining power of suppliers tends to be moderate.
1.1.5 Intensity of Rivalry
The degree of competition in the global dermal fillers market is moderate to high. The reserved degree of product differentiation among existing players increases the intensity of rivalry in the market. Aesthetic and skincare companies are trying to develop less expensive products to make these products more affordable in developing markets. To overcome the competition, players are engaged in developing a process to lower their manufacturing costs. Moreover, the players are also developing advanced products for differentiating their brand from their competitors.
Market estimates by geography (2025)
InsightNorth America leads with $2.29B by 2025, while Asia Pacific is projected to grow fastest at a 14.4% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2016 | 2018 | 2025 | CAGR | SHARE |
|---|---|---|---|---|---|
| Middle East and Africa | $79.82M | $133.60M | $201.08M | 10.8% | 3% |
| North America | $746.84M | $1.39B | $2.29B | 13.3% | 33% |
| Asia Pacific | $505.60M | $987.52M | $1.69B | 14.4% | 25% |
| Europe | $666.35M | $1.25B | $2.08B | 13.5% | 30% |
| South America | $252.01M | $423.39M | $638.41M | 10.9% | 9% |
| Total | $2.25B | $4.19B | $6.90B | 13.3% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$6.90B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Hyaluronic Acid | $2.92B | 13.3% | 72% |
| Polymers & Particles | $1.87B | 13.3% | 85% |
| Calcium Hydroxylapatite | $1.47B | 13.3% | 82% |
| Collagen | $640.76M | 13.3% | 89% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on aesthetics Market covering market dynamics, competitive landscape, and strategic outlook.
The aesthetics Market market is projected to reach $6.90B by 2025, growing at 13.3% CAGR. The Hyaluronic Acid segment holds the largest share.
The global market for aesthetics is growing on the preliminary backgrounds of various factors. The growth of the aesthetics market is mainly driven by the high demand for liposuction, hair transplantation, the rising obese and geriatric population, growing expenditure on cosmetic surgeries, prevalence of skin diseases, technological advancements in the aesthetic industry, and increasing acceptance of facial aesthetics. However, high procedural costs and sophistication and training associated with aesthetic procedures may slow the growth of the market during the forecast period.
With the cutting-edge technology employed by major players, coupled with the increasing innovation and research in the field of aesthetics, a lot of new entrants, as well as established players, are focusing on product differentiation and incorporation of innovation in their present dermal filler portfolio. Major companies are increasing their research and development in the aesthetics field and are focused on getting new products in the dermal fillers market in the coming years. For instance, in October 2019, Galderma, a global skin health company, announced the initiation of seven new clinical trials, including neurotoxin and dermal filler candidates. The company initiated clinical studies to support potential new aesthetic indications, including a tear trough indication for Restylane and a facial wrinkle indication for Sculptra. The company currently has enrolled more than 6,000 patients across approximately 80 clinical trial sites, with a total of 17 clinical studies underway. Such strategies are going to deduce heavy demand for the current dermal fillers in the market and promise to create lucrative opportunities for the growth of the global market in the coming years.
Galderma continues to support female clinical trial investigators and has doubled the number of female clinical investigators in company-sponsored trials since 2014. As in 2019, women clinical investigators hold approximately 50 percent of Galderma’s clinical investigator roles. Such strategies aid in increasing the target audience and potential customers of the company, which will surely drive the dermal fillers market growth in the near future.
One of the most common factors restraining the growth of the global dermal fillers market is the associated side-effects of dermal fillers. The Food and Drug Administration (FDA) has issued several notices to social healthcare suppliers and the general population about genuine complications that can occur if dermal fillers are unintentionally infused into blood vessels of the face. The inconveniences could incorporate vision hindrance, visual deficiency, stroke, and damage or necrosis of the skin and hidden facial structures. A paper released in 2018 by the Australasian Journal of Plastic and Reconstructive Surgery, stated that nearly 200 people suffered blindness after receiving dermal fillers across the globe in the year 2017. Caution should be taken to guarantee appropriate placement of the filler material, and patients must be educated about potential adverse impacts and how to perceive side-effects of approaching genuine complications.
Furthermore, with every medical procedure, there is a degree of risk associated with the use of facial injectables or dermal fillers. These adverse events may be injection-related, technique-related, or rarely may be owing to localized exposure to hyaluronic acid itself or potential residual purification solvents. Thus, complications during these procedures can prove to be a restraining factor for the global dermal fillers market.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 109 companies operating in the aesthetics Market market, including revenue, employee count, and market positioning where available.
Showing 109 of 109 companies
Medytox
Company Headquarters: Seoul, South Korea Founded: 2000 Workforce: ~280 Company Working: Medytox is a pharmaceutical company that manufactures, markets, and distributes medical aesthetics products across the globe. The company operates through business segments including, botulinum toxin products hyaluronic acid filler medical devices, and prescription drugs. Additionally, the company provides comfort dual, a medical device for tissue coagulation by using a high-frequency, and presently, Medytox exports its products to about 60 countries, including Brazil and Japan. company is planning to expand its business in the Americas and European countries through its subsidiaries Medytox US, Medybloom China, Medytox Taiwan, Medytox Hong Kong, MedyCeles, and MDT International (Japan). It has three manufacturing plants and one R&D center based in South Korea.
SciVision Biotech Inc.
Company Headquarters: Taiwan Founded: 2001 Workforce: ~15 Company Working: SciVision Biotech Inc. is involved in the manufacturing and marketing of hyaluronic acid products in Taiwan. The company operates through the following segments, namely, absorbable adhesion barriers, dermal implants, synovial fluid supplements, intravesical instillations, and skincare products. The company operates through several business areas, such as aesthetics and skincare.
Suneva Medical
Company Headquarters: California, US Founded: 2009 Workforce: ~104 Company Working: Suneva Medical Inc., is a medical technology company. It is engaged in the manufacturing and distribution of aesthetics and skincare products. The company offers products to treat acne, wrinkles, and skin regeneration. The US, Canada, South Korea, Hong Kong, and Singapore are the major markets covered by Suneva Medical, Inc. In 2017, the company celebrated ten years of its flagship brand, Bellafill. Moreover. The firm's recently enlarged portfolio offers suppliers cutting-edge, scientifically supported products that aim to solve important patient needs safely and effectively.
Teoxane Laboratories
Company Headquarters: Geneva, Switzerland Founded: 2003 Workforce: ~500 Company Working: Teoxane Laboratories (Teoxane) is specialized in the designing and manufacturing of hyaluronic acid (HA)-based dermal fillers and cosmeceuticals. The company offers skin treatment products that are used for reducing wrinkles, restoring youthful volume to the face, and treating the neck and décolleté with-looking natural results. It focuses on medical devices, aesthetic products, skin care, beauty, anti-aging solutions, dermal fillers, and dermis redensification. The company has a strong distribution network in more than 95 countries as well as more than 10 subsidiaries in France, UK, Italy, Spain, Germany, Switzerland, Poland, Australia, Russia, Dubai, and Singapore.
Sinclair Pharma
Company Headquarters: London, UK Founded: 1971 Workforce: 1,000 Company Working: Sinclair Pharma is a global healthcare company engaged in the development, manufacture, and distribution of pharmaceutical products. Other medical offerings of the company include aesthetics and cosmetic products. It has a portfolio of differentiated complementary aesthetics technologies with a focus on collagen stimulation. The company constitutes a huge network of international distributors throughout the world. Sinclair Pharma operates as a subsidiary of Huadong Medicine Co., Ltd.(China). The company has a strong presence in Europe, as well as the US, Brazil, and South Korea
Dr. Korman Laboratories
Company Headquarters: Kiryat Bialik, Israel Founded: 2015 Workforce: ~200 Company Working: DR. Korman is a rapidly growing medical device company involved in developing, manufacturing, and selling bio revitalization products, mesotherapy products, calcium hydroxyapatite (CaHA), and dermal fillers, among others. The company also manufactures intra-articular hyaluronic acid (IAHA) in different dosages for various indications such as pain and restricted mobility and degeneration of the knee joint and other synovial joints as well as osteoarthritis. DR. Korman, although based in Israel, operates in Western, Central, and Eastern Europe.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
aesthetics Market